Nuwellis Inc vs Nasdaq100 ETF — how do they compare? Nuwellis Inc trades at $1.4 (market cap $542.80K), while Nasdaq100 ETF trades at $724.25. The key difference: Nasdaq100 ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | QQQ | |
|---|---|---|
Market Cap | $542.80K | — |
Sector | Technology | — |
52-Week High | $220.50 | $746.16 |
52-Week Low | $1.42 | $558.34 |
Enterprise Value | -$1.27M | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.43, up 0.7% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of -$17.52M in 2025, with a negative net income margin of -217.22%, though recent news highlights product development and revenue growth initiatives, including a 14% preliminary year-over-year revenue increase in Q2 2026.
Outlook is cautious due to persistent losses and high cash burn, but growth in pediatric installations and strategic expansions offer potential. Risks include financial sustainability and competitive pressures, while analyst coverage is limited with a split buy/hold consensus.
QQQ trades at $725.43, up 0.64% with a bullish technical signal from moving averages. The ETF shows strong institutional interest with Ferguson Shapiro LLC increasing its position by 2,685.7% according to SEC filings. Recent news highlights Nasdaq's tech-led rally potential in H2 2026, with momentum and Fed liquidity supporting further upside according to Zacks Investment Research.
Outlook remains positive given historical performance and current technical strength, though RSI levels suggest potential near-term consolidation. Key risks include ETF expense ratios and market volatility, while opportunities lie in continued tech sector leadership and institutional accumulation patterns.
Trailing returns across standard periods
Latest headlines on both assets
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →